NCT01629732

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

Conditions

• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	Daclatasvir	Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
DRUG	Daclatasvir	Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
DRUG	BMS-986094	Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
DRUG	BMS-986094	Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
DRUG	BMS-986094	Capsule, Oral, 200 mg, Once daily, 24 Weeks
DRUG	Ribavirin	Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
DRUG	Placebo for BMS-986094	Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-02-01
• Completion: 2014-06-01
• First posted: 2012-06-28
• Last updated: 2014-05-09

Locations

1 site across 1 country: United States